Rare/Orphan Diseases Track at DIA's 49th Annual Meeting

	Is there a recipe for successful implementation of Registries for RareDiseases?
	What is the emerging role of Crowdsourcing in Rare Disease research?
	What incentives are available in US, EU and Japan to develop orphan medicines?
	How can my organization engage with rare disease patient communities to develop treatment?
	What are the challenges inherent in drug rescue and repurposing for rare disease and orphan products?
	How do developers demonstrate the value of rare disease products to payer regulators?
	What are the challenges facing development of new orphan drugs?